CD274 and neoplasm: The increased expression of PD-L1 by tumour or infiltrating immune cells, high mutational loads and increased densities of tumour-infiltrating lymphocytes (TILs), are the most promising biomarkers that best correlate with efficacy of immunotherapy in some cancers[47–50].